{@!--LOGTO_LOGIN_BUTTON--!@}
December 9, 2025 11:19 AM EST
Deals
AI

No­var­tis to part­ner with AI-fo­cused Re­la­tion on atopic dis­eases

Ayisha Sharma

News Reporter

No­var­tis has inked a deal with UK biotech Re­la­tion to dis­cov­er and de­vel­op new drugs for cer­tain im­mune dis­eases.

This is the sec­ond deal with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Think we're worth reading - tell Google.

Confirm Endpoints as a trusted biopharma news source

ENDPOINTS CAREERS

Senior Director, Licensing Officer

Bayer

Cambridge, MA, USA

TRENDING NOW

'We're para­noid.' As Chi­na biotech com­pe­ti­tion heats up, Amer­i­can drug­mak­ers get more se­cre­tive

Ger­man law­mak­ers pass cost-sav­ing bill that drug­mak­ers say will dri­ve them out

FDA re­turns to re­leas­ing phar­ma re­jec­tion let­ters with 14 new CRLs

FDA re­jects Hen­grui-El­e­var liv­er can­cer drug com­bo for third time

Pfiz­er ap­points obe­si­ty dis­cov­ery head; AI start­up Xaira makes lead­er­ship ad­just­ments

Han­soh meets Phase 3 SCLC goal; FDA ap­proves Sanofi on-body in­jec­tor

A service from the Financial Times